Hematology · 2018 · 17 citations · 24 references
Life SciencesMolecular BiologyOncologyCell SignalingGene ExpressionTranscriptional RegulationApoptosis ResistanceChromatinMyeloproliferative NeoplasmsOncogenic Signaling PathwaysReceptor Tyrosine Kinase SignalingBcr-abl InhibitorsBeta-catenin RegulationCancer Cell Survival SignalingCanonical Wnt PathwayChronic Myeloid Leukemia TherapyMyeloproliferative Neoplasm TreatmentOncogene Expression AnalysisWestern Blot Analysis
OBJECTIVE: Chronic myleoid leukemia (CML) is a myeloproliferative disorder characterized with the constitutive activation of Bcr-Abl tyrosine kinase which is a target for imatinib, the first line treatment option for CML. Constitutive activation of NFκB and β-catenin signaling promotes cellular proliferation and survival and resistance to Imatinib therapy in CML. Akirin-2 is a nuclear protein which is required for NFκB dependent gene expression as a cofactor and has been linked to Wnt/beta-catenin pathway. The purpose of this study is to examine Akirin-2, NFκB and β-catenin in imatinib resistance of CML and to test if any direct physical protein-protein interaction exists between NFkB and both β-catenin and Akirin-2. METHODS: RT-PCR and western blot were performed to determine Akirin-2, NFκB-p65 and β-catenin gene and protein expressions, Co-immunoprecipitation and chromatin immunoprecipitation analysis were carried out to detect the direct physical interactions and binding of NFκB-p65 and β-catenin proteins to MDR1 promoter region, respectively. RESULTS: β-catenin and NFκB-p65 proteins bound to DNA promoter regions of MDR1 in imatinib-sensitive and resistant CML cells, whereas any direct protein-protein interaction could not be found between NFκB-p65 and Akirin-2 or β-catenin proteins. Nuclear β-catenin and NFκB-p65 levels increased in imatinib resistance. Moreover, increased Akirin-2 protein accumulation in the nucleus was shown for the first time in imatinib resistant CML cells. DISCUSSION: We show for the first time that Akirin-2 can be a novel biomarker in imatinib resistance. Targeting Akirin-2, NFκB and β-catenin genes may provide an opportunity to overcome imatinib resistance in CML.
24
Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells
Mónica L. Guzmán, Sarah J. Neering, Donna Upchurch et al. · Blood · 2001 · 757 citations
Medicine, Cell Biology, Oncology +7
NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells
Mohamed Bentires‐Alj, Véronique Barbu, Marianne Fillet et al. · Oncogene · 2003 · 430 citations · Full text
Medicine, Oncology, Pharmacology +12